Login to Your Account

Positive Safety Profile, Too

Threshold Nails PFS Endpoint In TH-302 Pancreatic Cancer Trial

By Marie Powers
Staff Writer

Wednesday, February 22, 2012
Threshold Pharmaceuticals Inc. saw shares rocket as high as 88 percent Tuesday morning after the company reported its Phase IIb study evaluating TH-302 in advanced pancreatic cancer hit its primary endpoint.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription